News

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and to increase human longevity, announce the publication…...

LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced today that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. Their technology uses lymph nodes as bioreactors to regrow…...

Dr. Greg Bailey, CEO of Juvenescence gives an interview to Longevity Technology to discuss his thoughts on the longevity field and future plans for Juvenescence. In the interview, Greg discusses the origins of Juvenescence as well as his belief that…...

Michael Hufford, CEO of Lygenesis, gives an interview to Longevity Technology about the revolutionary Lygenesis technology and their plans for clinical development. Lygenesis' technology will enable the use of patients lymph nodes as bioreactors to regrow functioning ectopic organs to…...

Insilico Medicine, a pioneer in next-generation artificial intelligence technology for drug discovery, recently completes a USD $37 million funding round led by Qiming Venture Partners, joined by Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital,…...

Juvenescence is impressed by Insilico Medicine's recent article in Nature Biotech, highlighting their ability to use deep learning for de novo small-molecule design. They have developed a deep generative model, generative tensorial reinforcement learning (GENTRL) to discover potent inhibitors of discoidin…...

Juvenescence pipeline company AgeX Therapeutics, a biotechnology company focused on therapeutics for human aging and regeneration, announced today that founder and CEO Michael D. West, Ph.D., and colleagues have authored a paper in the peer-reviewed scientific journal Regenerative Medicine on…...

Juvenescence is encouraged by Forbes’ recent article, highlighting the exponential nature in which scientific breakthroughs are occurring in anti-aging research. The fundamental biological processes that lead to aging are being increasingly understood, due to the convergence of scientific knowledge with…...

Juvenescence, a life sciences company utilising expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human longevity, is pleased to announce the successful closure of its $100 million Series…...

Juvenescence is encouraged by Bank of America Merrill Lynch’s recent report, ‘Immortal combat – Future Human Primer’, where their analysts have highlighted the impending growth of longevity-focused companies. They estimate that the market for ‘techmanity’, technology to increase human lifespan,…...

Juvenescence announces that Colin Watts has joined its Management Team as CEO of Juvenescence Life. As a new division of the company, Juvenescence Life is focused on the commercialization of scientifically proven and branded health supplements, nutraceuticals, and medical foods…...

Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration. Souvien is founded on the pioneering research of Professor Li-Huei Tsai, the director of…...

  • 1
  • 2